Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab-iCHOP versus rituximab high-dose sequential therapy with autologous stem cell transplantation for high-risk DLBCL
ISRCTN46136861Phase 3Completed
- Sponsor
- HOVON
- Start
- Oct 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone and 6 more in diffuse large B-cell lymphoma (DLBCL) and non-Hodgkin lymphoma (NHL) (2 arms), sponsored by HOVON. Primary endpoint: Event-free survival. Started Oct 2005; status: completed.
02
Drugs
rituximabcyclophosphamidedoxorubicinvincristineprednisone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on ISRCTN46136861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN46136861.